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The recognition of
microorganisms by T cells is the
central event in the adaptive
immune response to infection.
Each T cell expresses a unique T-
cell antigen receptor (TCR), which
recognizes microorganism-
derived peptides presented on
cell-surface major
histocompatibility complex (MHC)
molecules. The binding of TCRs to
peptide-bound MHC (pMHC) with
high affinity leads to a series of
signalling events culminating in
cellular responses such as
proliferation, differentiation and
secretion of cytokines and growth
factors. Although the TCR signal
transduction pathways have been
intensively studied, it is still not
clear how binding of pMHC to
TCR is initially communicated
across the T-cell plasma
membrane, a process termed TCR
triggering [1–3]. We review here
two recent studies that shed light
on the TCR triggering mechanism
and help to reconcile much of the
existing conflicting data [4,5].
TCRs are composed of two
transmembrane subunits (α and β)
with very short cytoplasmic tails
that are non-covalently associated
with several signalling subunits.
The latter have cytoplasmic motifs
that are modified by tyrosine
phosphorylation and recruit
cytoplasmic signalling molecules.
A typical TCRαβ is associated
with at least six signalling
subunits, including CD3εγ and
CD3εδ heterodimers and a TCRζζ
homodimer. Also important for
signalling are the CD8 or CD4
‘coreceptors’, which bind to the
non-variable MHC portion of the
pMHC class I (pMHCI) and pMHC
class II (pMHCII) complexes,
respectively, and whose
cytoplasmic domains bind to the
tyrosine kinase Lck.
Models proposed for TCR
triggering can be classified into
three categories according to
whether they invoke aggregation,
conformational change, or
segregation of the TCR–CD3
complex as the primary
mechanism of signal transduction
(Figure 1). Aggregation models are
supported by the observation that
artificial aggregation of TCR–CD3,
using either antibodies or
multivalent forms of soluble
agonist (high affinity) pMHC, is
sufficient for TCR triggering.
However, the paucity of agonist
pMHC on cells and the more
recent finding that a single agonist
pMHC is alone sufficient for TCR
triggering in CD4+ or CD8+ T cells
[6,7] seemed to rule out
aggregation mechanisms. 
Now Krogsgaard et al. [4] report
that MHC class II molecules
bearing peptides derived from
endogenous proteins (endogenous
pMHCII), which are presumably
low affinity and unable to induce
TCR triggering on their own,
enhance TCR triggering by MHC
class II molecules bearing agonist
peptides. This was demonstrated
using soluble agonist–endogenous
pMHCII heterodimers as well as
mixtures of agonist and
endogenous pMHC on artificial
membranes and cells. Because
endogenous pMHCII is highly
abundant on antigen-presenting
cells, it is indeed plausible that
TCR aggregation could be induced
by such a mixture of endogenous
and agonist pMHC. 
Krogsgaard et al. [4] go on to
show, using mutated forms of
pMHCII, that CD4 binding to
agonist pMHCII was required for
this effect whereas CD4 did not
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Immunology: How Do T Cells
Recognize Antigen?
T cells recognize small fragments of microorganisms (antigens) on the
surface of other cells using T cell antigen receptors. The mechanism
by which these receptors signal into T cells is controversial, but two
recent studies provide important new clues. 
need to bind endogenous pMHCII
(Figure 2). This finding is
particularly interesting in the light
of earlier studies showing that a
substantial proportion of TCRs are
constitutively associated with
coreceptors [8,9], and that
coreceptors bind pMHC at an
angle that appears to preclude
directly associated TCRs and
coreceptors from binding the
same pMHC complex (reviewed in
[10]). Taken together, these data
suggest a model in which a
TCR–CD4 complex is brought
together with an agonist pMHCII-
engaged TCR by the TCR binding
to endogenous pMHCII and the
CD4 binding to the agonist
pMHCII (Figure 2).
At first glance this model does
not seem to apply to CD8+ T cells.
Firstly, it has been shown that
endogenous pMHCI does not
seem to enhance recognition of
agonist pMHCI by CD8 cells [11].
Secondly, there is evidence, albeit
controversial, that soluble
monovalent forms of pMHCI are
sufficient to trigger TCRs on some
CD8+ T cells [3]. This apparent
difference between CD4+ and
CD8+ T cells can be reconciled if it
is assumed that the affinity of CD4
binding to pMHCII is much lower
than the affinity of CD8 binding to
pMHCI. Indeed, whereas several
groups have demonstrated
soluble CD8 binding to pMHCI
and measured broadly similar
affinity constants, binding of
soluble forms of CD4 to pMHCII
has been far more difficult to
demonstrate, consistent with a
severalfold lower affinity [12]. 
We propose that the affinity of
the CD8–pMHCI interaction is
sufficient to drive recruitment of
a CD8–TCR–CD3 complex and
therefore initiate triggering
(Figure 2). In contrast, the
CD4–pMHCII interaction is too
weak to drive recruitment of
CD4–TCR–CD3 complexes and
an additional interaction between
the TCR and endogenous pMHCII
is also required (Figure 2). Why
might there be this difference
between CD4+ and CD8+ T cells
in their dependence on
endogenous pMHC for
triggering? One possible
explanation is that, whereas
TCRs on CD4+ T cells recognize
antigen on a small group of
‘professional’ antigen-presenting
cells, TCRs on CD8+ T cells need
to recognize antigen on a diverse
variety of cell types. Since each
cell type would express a
different set of lineage-specific
proteins, they will present a
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Figure 1. Models of TCR triggering that are compatible with current knowledge.
(A) Aggregation leads to triggering by induced proximity of tyrosine kinases such as Lck and their substrates. At higher surface den-
sities of agonist pMHC, aggregation can be induced independent of coreceptor engagement. With low levels of agonist pMHC, 
coreceptor engagement is necessary for aggregation and may be dependent on endogenous pMHC (Figure 2). (B) Conformational
change may either involve a conformational change between the TCRαβ and CD3 signalling subunits or a piston-like movement of
the TCR and/or CD3. In both cases the changes are postulated to result from a mechanical pulling force exerted on the TCR by pMHC
binding and could lead to conformational changes in the cytoplasmic tails of the CD3 subunits. (C) Segregation leads to triggering by
placing the TCR–CD3 complex in an environment enriched in molecules that promote TCR triggering, such as Src tyrosine kinases
and their substrates, and deficient in molecules that inhibit triggering, such as membrane tyrosine phosphatases (e.g. CD45). Lipid
rafts are enriched in tyrosine kinases and depleted of CD45. In the kinetic segregation model pMHC engagement holds the TCR–CD3
complex in a close contact zone from which CD45 and CD148 are excluded because of the large size of their ectodomains. 
*
Kinetic segregation
B    Conformational change C    SegregationA    Aggregation
*
Change between
TCR and CD3
* *
Coreceptor-
independent
Coreceptor-assisted
* *
Piston-like movement
*
*
Lipid raft association
**
Current Biology
*
TCR
Key
CD3
complex
CD3 -
inactive
conformation
Src family
tyrosine
kinase
MHC
Phosphotyrosine
Membrane
tyrosine
phosphatase
MembraneCoreceptorAgonist
pMHC
Endogenous
pMHC
Lipid
raft
APC
T cell
different spectrum of
endogenous pMHCI, with the
result that antigen recognition by
CD8+ T cells would be
inappropriately dependent on the
cell lineage.
A second mechanism proposed
for TCR triggering is binding-
induced conformational change
(Figure 1B). In another recent
study, Gil et al. [5] provide
evidence for such a change by
showing that, when T cells
recognise agonist pMHC on other
cells, the cytoplasmic tail of CD3ε
acquires the ability to bind directly
to the cytoplasmic adaptor
molecule Nck. In an earlier study
Gil et al. [13] provided strong
evidence in a cell-free system that
this ability to bind Nck involved a
conformational change in the
cytoplasmic tail. The interaction is
mediated by direct binding of the
Nck Src homology 3 (SH3) domain
to a proline-rich, membrane-
proximal portion of the CD3ε
cytoplasmic domain [5,13].
Overexpression of the Nck SH3
domain blocked some T-cell
responses to pMHC engagement,
consistent with a role for this
interaction in TCR triggering [13]. 
How might pMHC binding
induce such a conformational
change? Structural studies have
ruled out long-range
conformational changes
transmitted through the TCRαβ
itself as a general mechanism,
because there is only one
reported example of such a
change [14] and it is not observed
in other TCRs [10]. More plausible
is a binding-induced change in
the relationship between two
TCRs and/or between a TCRαβ
and its associated signalling
subunits (Figure 1B). For
example, the unbound TCRαβ
may ‘slouch’ on the T-cell
surface. When it binds ligand, the
mechanical force applied to it by
the engaged pMHC would cause
it to ‘stand up straight’, thereby
changing its position relative to
the signalling subunits. 
An alternative possibility is that
the mechanical force imposed by
binding pulls the TCR and
associated CD3 components
towards the APC in a piston-like
movement. The resulting change
in the positions of transmembrane
and/or cytoplasmic portions of
TCR–CD3 relative to the
membrane could result in
conformational changes in the
TCR–CD3 cytoplasmic tails such
as ‘opening’ of the Nck-binding
site on CD3ε. Davis has proposed
a piston-like mechanism in which
pMHC binding pushes the
TCR–CD3 into the membrane [2].
A pulling piston-like mechanism
has the advantage that, because it
requires binding, it is inherently
specific. In contrast, a pushing
mechanism could be triggered by
non-specific steric repulsion.
Finally, a third type of
mechanism that has been
proposed for TCR triggering is
binding-induced segregation of
TCR–CD3 from inhibitory
molecules such as tyrosine
phosphatases (Figure 1C).
Segregation could be driven by
association with lipid rafts [15] or
differences in the ectodomain size,
as proposed in the kinetic
segregation model [16,17]. The
role of lipid raft association is
controversial as different
techniques have produced
conflicting evidence [18]. Recent
evidence in support of a size-
based mechanism include the
demonstration that TCR triggering
is inhibited by truncation of the
CD45 [19] and CD148 [20]
ectodomains and by elongation of
the TCR–pMHC complex (K.C., D.
Wiseman, M.H. Brown, K. Gould,
and P.A.v.d.M., unpublished data).
Although a number of
mechanisms have been
implicated in TCR triggering, it
should be emphasised that they
are not mutually exclusive, and
triggering may involve
combinations of conformational
change, aggregation, and
segregation mechanisms. Clearly,
a lot more work is required to
resolve this issue. Important
strategies for future research are
determining the structure of the
native TCR–CD3 complex,
analysis of the mechanical
properties of the TCR–pMHC
interactions and the effect of
mechanical forces on TCR
triggering, development of
mathematical models of TCR
triggering that incorporate the
large amount of available data,
and incisive perturbation (such as
mutagenesis or knockdown)
experiments to test these models.
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Figure 2. Coreceptor-assisted TCR aggregation.
Coreceptors and TCR complexes are associated on the resting T-cell surface [8,9].
Coreceptor–MHC interactions can therefore drive TCR association even at very low
densities of agonist pMHC. Due to its low affinity, the CD4–pMHCII interaction is insuf-
ficient to drive TCR aggregation, and TCR binding to endogenous pMHC is also
required. In contrast, the CD8–pMHCI interaction is of sufficiently high affinity to drive
TCR aggregation, even in the absence of endogenous pMHC.
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F0F1 ATP synthase is a ubiquitous
and highly conserved enzyme,
found in the cytoplasmic
membrane of prokaryotes and in
the mitochondria of eukaryotes,
which synthesizes most of the
ATP used by most organisms on
the planet. The rotary mechanism
of this enzyme is well-established
[1–5]. F0 is a membrane-bound
rotary motor driven by the
protonmotive force, an
electrochemical ion gradient
across the membrane. F1 is also a
rotary motor, but driven by ATP
hydrolysis [6–8]. In the complete
F0F1 enzyme the rotors (γ and ε
subunits in F1 and the c-ring in F0)
and stators (α3β3δ in F1 and a and
b subunits in F0) of both motors
are joined together, so that
rotation of the two motors is
directly coupled. The orientation
of the motors is such that they are
trying to rotate in opposite
directions. Under normal
physiological conditions F0 is
stronger: thus F0 rotates forwards
and drives F1 in reverse, and the
overall result is the synthesis of
ATP driven by the protonmotive
force (Figure 1A).
A great deal has been learned
recently about the mechanism of
F1 operating in the forwards, ATP-
hydrolysing direction by
observing the rotation of various
markers attached to the rotor [8].
The enzyme takes one 120° step
for every ATP molecule
hydrolyzed. This step is divided
into sub-steps of 80° and 40°,
triggered by ATP binding and by
hydrolysis or product release,
respectively [5,8]. However, much
less is known about ATP
synthesis. 
In a recent study, Rondelez et
al. [9] made accurate quantitative
measurements of both ATP
hydrolysis and synthesis coupled
to rotation of single F1 molecules
in either direction. They were able
to detect the presence or
absence of a few thousand ATP
molecules by following the
rotation of a single F1 molecule in
a sealed microchamber. With F1
running forwards and using up
ATP in the chamber,
measurements of the rate of
slowing of rotation confirmed that
one F1 molecule hydrolyses three
ATP molecules per revolution.
This result had been inferred
previously, but not directly
demonstrated. 
By pushing F1 backwards to
synthesize ATP and subsequently
measuring the increased forwards
rotation rate of the same
molecule, Rondelez et al. [9]
found that each F1 molecule also
synthesizes three ATP molecules
per revolution, thus
demonstrating that the enzyme is
tightly coupled in both directions.
They also confirmed the
importance of the ε-subunit,
which was necessary for coupling
backwards rotation to synthesis
but not for coupling hydrolysis to
forwards rotation.
The most significant technical
advance in the work of Rondelez
et al. [9] is the confinement inside
sealed chambers with volumes of
a few cubic microns of single
rotating F1 molecules with
magnets attached to the rotor.
600 revolutions of F1 synthesize or
hydrolyze 1800 molecules of ATP,
producing a concentration change
of 0.1 µM in such a small
chamber. The corresponding
change in the speed of rotation of
ATP Synthesis: The World’s
Smallest Wind-Up Toy
ATP synthase contains two rotary motors coupled back-to-back: the
protonmotive force-driven motor F0 pushes the ATP-driven motor F1 in
reverse, causing it to synthesize ATP. Half of this process has now
been reproduced in vitro, using tiny magnets instead of F0 to drive the
reverse rotation of a single F1 molecule.
